iGene to Participate in 2023 BIO USA... Introducing mRNA Vaccine Technology

iGene announced on the 22nd that it will participate in '2023 BIO USA,' the world's largest pharmaceutical and biotech convention, held in Boston, USA, from the 5th to the 9th of next month.

Eugene Logo
Photo by Eugene

iGene will join the Korean Pavilion booth, supported by the Ministry of Trade, Industry and Energy and organized by the Korea Bio Association and the Korea Trade-Investment Promotion Agency (KOTRA), and plans to conduct partnering with over 20 global pharmaceutical companies during the event.

At this event's partnering sessions, iGene plans to promote the global commercialization of mRNA-based vaccine technology using the cationic liposome-structured messenger ribonucleic acid (mRNA) delivery system "EG-R" and recombinant shingles vaccine (EG-HZ) technology containing a cationic liposome-structured immune adjuvant. iGene is developing a COVID-19 vaccine using EG-R that can be stored refrigerated and has significantly reduced side effects. Clinical Phase 2a booster trials for the first virus strain, Wuhan strain, and Omicron variant-specific vaccines, 'EG-COVID' and 'EG-COVARo,' are currently underway in Australia.

An iGene representative stated, "At this BIO USA event, we will focus not only on introducing iGene's COVID-19 vaccine utilizing our delivery system but also on presenting 'iPT,' the mRNA-based personalized cancer vaccine system developed by Renaim, which is conducting cancer vaccine research and development using iGene's delivery system."